Cargando…

Complexity of FGFR signalling in metastatic urothelial cancer

BACKGROUND: Urothelial cancers (UC) are the fourth most common tumours worldwide after prostate (or breast), lung and colorectal cancer. Despite recent improvements in their management, UC remain an aggressive disease associated with a poor outcome. Following disease progression on first-line platin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rodriguez-Vida, Alejo, Saggese, Matilde, Hughes, Simon, Rudman, Sarah, Chowdhury, Simon, Smith, Neil R., Lawrence, Peter, Rooney, Claire, Dougherty, Brian, Landers, Donal, Kilgour, Elaine, Arkenau, Hendrik-Tobias
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4619431/ https://www.ncbi.nlm.nih.gov/pubmed/26497743 http://dx.doi.org/10.1186/s13045-015-0221-6

Ejemplares similares

Enzalutamide for the treatment of metastatic castration-resistant prostate cancer
por: Rodriguez-Vida, Alejo, et al.
Publicado: (2015)

Research Biopsies in the Context of Early Phase Oncology Studies: Clinical and Ethical Considerations
por: Saggese, Matilde, et al.
Publicado: (2013)

FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder
por: Guancial, Elizabeth A, et al.
Publicado: (2014)

Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer
por: Facchinetti, Francesco, et al.
Publicado: (2023)

Development and Evaluation of a New Technological Way of Engaging Patients and Enhancing Understanding of Drug Tolerability in Early Clinical Development: PROACT
por: Hughes, Andrew, et al.
Publicado: (2016)

Erratum to: Development and Evaluation of a New Technological Way of Engaging Patients and Enhancing Understanding of Drug Tolerability in Early Clinical Development: PROACT
por: Hughes, Andrew, et al.
Publicado: (2016)

Role of FGFR3 in Urothelial Carcinoma
por: Akanksha, Malik, et al.
Publicado: (2019)

FGFR2/3 genomic alterations and response to Enfortumab Vedotin in metastatic urothelial carcinoma
por: Adib, Elio, et al.
Publicado: (2021)

Infigratinib in Early-Line and Salvage Therapy for FGFR3-Altered Metastatic Urothelial Carcinoma
por: Lyou, Yung, et al.
Publicado: (2022)

Novel Treatments for Metastatic Cutaneous Melanoma and the Management of Emergent Toxicities
por: Lemech, Charlotte, et al.
Publicado: (2012)

Prognostic Value and Clinical Significance of FGFR Genomic Alterations (GAs) in Metastatic Urothelial Cancer Patients
por: Sevillano Fernández, Elena, et al.
Publicado: (2022)

Immunotherapy With Checkpoint Inhibitors in FGFR-Altered Urothelial Carcinoma
por: Benjamin, David J, et al.
Publicado: (2022)

Characterization of FGFR1 Locus in sqNSCLC Reveals a Broad and Heterogeneous Amplicon
por: Rooney, Claire, et al.
Publicado: (2016)

Targeting the Src Pathway Enhances the Efficacy of Selective FGFR Inhibitors in Urothelial Cancers with FGFR3 Alterations
por: Lima, Nadia Carvalho, et al.
Publicado: (2020)

Fibroblast Growth Factor Receptor (FGFR) Inhibitors in Urothelial Cancer
por: Garje, Rohan, et al.
Publicado: (2020)

FGFR3 Alterations in the Era of Immunotherapy for Urothelial Bladder Cancer
por: Kacew, Alec, et al.
Publicado: (2020)

Pure Large Nested Variant of Urothelial Carcinoma (LNUC) Is the Prototype of an FGFR3 Mutated Aggressive Urothelial Carcinoma with Luminal-Papillary Phenotype
por: Weyerer, Veronika, et al.
Publicado: (2020)

Futibatinib, an Irreversible FGFR1–4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF/FGFR Aberrations: A Phase I Dose-Expansion Study
por: Meric-Bernstam, Funda, et al.
Publicado: (2022)

Recent Progress in the Systemic Treatment of Advanced/Metastatic Cholangiocarcinoma
por: Fostea, Raluca Maria, et al.
Publicado: (2020)

BGJ398, A Pan-FGFR Inhibitor, Overcomes Paclitaxel Resistance in Urothelial Carcinoma with FGFR1 Overexpression
por: Kim, Se Hyun, et al.
Publicado: (2018)

ASP5878, a selective FGFR inhibitor, to treat FGFR3‐dependent urothelial cancer with or without chemoresistance
por: Kikuchi, Aya, et al.
Publicado: (2017)

Treatment approaches for FGFR-altered urothelial carcinoma: targeted therapies and immunotherapy
por: Benjamin, David J., et al.
Publicado: (2023)

Involvement of FGFR4 Gene Variants on the Clinicopathological Severity in Urothelial Cell Carcinoma
por: Tsay, Ming-Dow, et al.
Publicado: (2019)

Development of resistance to FGFR inhibition in urothelial carcinoma via multiple pathways in vitro
por: Pettitt, Geoffrey A, et al.
Publicado: (2022)

Case Report: Anlotinib Combined With Sintilimab as Third-Line Treatment in a Metastatic Urothelial Bladder Carcinoma Patient With FGFR3 Mutation
por: Cao, Jian-zhou, et al.
Publicado: (2021)

PD‐L1 expression and FGFR‐mutations among Danish patients diagnosed with metastatic urothelial carcinoma: A retrospective and descriptive study
por: Grantzau, Trine, et al.
Publicado: (2022)

Metastatic urothelial carcinoma()()
por: Gómez-Moyano, Elisabeth, et al.
Publicado: (2021)

Incidence of FGFR2 Amplification and FGFR2 Fusion in Patients with Metastatic Cancer Using Clinical Sequencing
por: Hyung, Sujin, et al.
Publicado: (2022)

Fibroblast growth factor receptor 3 (FGFR3) aberrations in muscle-invasive urothelial carcinoma
por: Kim, Young Saing, et al.
Publicado: (2018)

Dabrafenib and trametinib activity in a patient with BRAF V600E mutated and microsatellite instability high (MSI-H) metastatic endometrial cancer
por: Moschetta, Michele, et al.
Publicado: (2017)

Combination Therapies for the Treatment of Advanced Melanoma: A Review of Current Evidence
por: Voskoboynik, Mark, et al.
Publicado: (2014)

Biomarkers in Advanced Colorectal Cancer: Challenges in Translating Clinical Research into Practice
por: Lemech, Charlotte, et al.
Publicado: (2011)

Oncology clinical trials during the COVID-19 outbreak: Lessons learnt during the crisis and future opportunities
por: Fontana, Elisa, et al.
Publicado: (2020)

Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo
por: Lamont, F R, et al.
Publicado: (2011)

Incidental detection of FGFR3 fusion via liquid biopsy leading to earlier diagnosis of urothelial carcinoma
por: Huang, Quillan, et al.
Publicado: (2023)

The 27-gene IO score is associated with efficacy of PD-1/L1 inhibitors independent of FGFR expression in a real-world metastatic urothelial carcinoma cohort
por: Nielsen, Tyler J., et al.
Publicado: (2023)

New treatment options for metastatic renal cell carcinoma
por: Rodriguez-Vida, Alejo, et al.
Publicado: (2017)

Update on the Treatment of Metastatic Urothelial Carcinoma
por: Bukhari, Nedal, et al.
Publicado: (2018)

ARID1A Alterations Are Associated with FGFR3-Wild Type, Poor-Prognosis, Urothelial Bladder Tumors
por: Balbás-Martínez, Cristina, et al.
Publicado: (2013)

FORT-1: Phase II/III Study of Rogaratinib Versus Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on FGFR1/3 mRNA Expression
por: Sternberg, Cora N., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_c7u0bngjgifsj8i2i806dq39ve